Who is sponsoring NCT03961828?

NCT03961828 is sponsored by Tanta University.

What drugs are being tested in NCT03961828?

Interventions in NCT03961828: Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni].

What condition does NCT03961828 study?

NCT03961828 studies Beta-Thalassemia, Hepatitis C.

Is NCT03961828 still recruiting?

NCT03961828 is currently completed. Last updated 23 May 2019.

Last reviewed 2019-05-23 · How we verify

NCT03961828

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus

Completed Phase 4 Last updated 23 May 2019

What this trial tests

Phase 4 trial testing Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni] in Beta-Thalassemia in 50 participants. Completed in 1 March 2019.

Timeline

1 October 2017

Primary endpoint
31 December 2018

1 March 2019

Quick facts

Lead sponsor	Tanta University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 October 2017
Primary completion	31 December 2018
Estimated completion	1 March 2019
Sites	1 location across Egypt

Drugs / interventions tested

Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni] — full drug profile →

Conditions studied

Beta-Thalassemia — all drugs for Beta-Thalassemia →
Hepatitis C — all drugs for Hepatitis C →

Sponsor

Tanta University

Who can join

Adults 12 to 18, any sex, with Beta-Thalassemia or Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with transfusion dependent Beta Thalassemia suffer from a high incidence of Hepatitis C infection especially in developed countries as Egypt. In our patients we also found a high correlation between hepatitic C infection and Liver fibrosis. in this study we offer our patients treatment with Direct antiviral drugs and assessed the degree of fibrosis before and after treatment. We tested Hyalornic acid as a predictor of the degree of fibrosis before and after treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Beta-Thalassemia

Currently open trials in the same condition.

NCT06364774 — ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia · Phase 1, PHASE2 · recruiting
NCT06568926 — Adherence of Beta Thalssemia Patients to Oral Chelation Therapy · NA · recruiting
NCT06539169 — FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases · recruiting
NCT06308159 — An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia · Phase 1, PHASE2 · recruiting
NCT06065189 — Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major · EARLY_PHASE1 · active not recruiting

Other Tanta University trials

Trials by the same sponsor.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03961828 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanta University
Last refreshed: 23 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03961828.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing